Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells.

James NE, Cantillo E, Oliver MT, Rowswell-Turner RB, Ribeiro JR, Kim KK, Chichester CO 3rd, DiSilvestro PA, Moore RG, Singh RK, Yano N, Zhao TC.

Clin Exp Immunol. 2018 May 10. doi: 10.1111/cei.13153. [Epub ahead of print]

PMID:
29745428
2.

Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer via Regulation of the Extracelluar Matrix.

Ribeiro JR, Gaudet HM, Khan M, Schorl C, James NE, Oliver MT, DiSilvestro PA, Moore RG, Yano N.

Front Oncol. 2018 Jan 22;7:332. doi: 10.3389/fonc.2017.00332. eCollection 2017.

3.

Cytoreductive surgery for ovarian cancer: quality assessment.

Brand AH, DiSilvestro PA, Sehouli J, Berek JS.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii25-viii29. doi: 10.1093/annonc/mdx448. Review.

PMID:
29232471
4.

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, Zaino RJ, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.

Gynecol Oncol. 2018 Jan;148(1):174-180. doi: 10.1016/j.ygyno.2017.10.037. Epub 2017 Nov 11.

5.

Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.

Creasman WT, Ali S, Mutch DG, Zaino RJ, Powell MA, Mannel RS, Backes FJ, DiSilvestro PA, Argenta PA, Pearl ML, Lele SB, Guntupalli SR, Waggoner S, Spirtos N, Boggess JF, Edwards RP, Filiaci VL, Miller DS.

Gynecol Oncol. 2017 Jun;145(3):519-525. doi: 10.1016/j.ygyno.2017.03.017. Epub 2017 Apr 6.

6.

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS.

Gynecol Oncol. 2017 May;145(2):236-242. doi: 10.1016/j.ygyno.2017.03.013. Epub 2017 Mar 22.

7.

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jeske YW, Ali S, Byron SA, Gao F, Mannel RS, Ghebre RG, DiSilvestro PA, Lele SB, Pearl ML, Schmidt AP, Lankes HA, Ramirez NC, Rasty G, Powell M, Goodfellow PJ, Pollock PM.

Gynecol Oncol. 2017 May;145(2):366-373. doi: 10.1016/j.ygyno.2017.02.031. Epub 2017 Mar 15.

8.

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.

Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, Thigpen JT, Lee YC, Tewari KS, Chino J, Seward SM, Miller DS, Salani R, Moore DH, Stehman FB.

Gynecol Oncol. 2016 Nov;143(2):294-301. doi: 10.1016/j.ygyno.2016.08.317. Epub 2016 Aug 17.

9.

Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

McMeekin DS, Tritchler DL, Cohn DE, Mutch DG, Lankes HA, Geller MA, Powell MA, Backes FJ, Landrum LM, Zaino R, Broaddus RD, Ramirez N, Gao F, Ali S, Darcy KM, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.

J Clin Oncol. 2016 Sep 1;34(25):3062-8. doi: 10.1200/JCO.2016.67.8722. Epub 2016 Jun 20.

10.

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ.

N Engl J Med. 2016 Feb 25;374(8):738-48. doi: 10.1056/NEJMoa1505067.

11.

Inherited Mutations in Women With Ovarian Carcinoma.

Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ.

JAMA Oncol. 2016 Apr;2(4):482-90. doi: 10.1001/jamaoncol.2015.5495.

12.

An Isolated Metastasis From Clear Cell Renal Cell Carcinoma to the Uterus: A Case Report and Review of Literature.

Singh K, DiSilvestro PA, Lawrence WD, Quddus MR.

Int J Gynecol Pathol. 2016 Sep;35(5):419-22. doi: 10.1097/PGP.0000000000000253. Review.

PMID:
26630224
13.

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.

Landrum LM, Brady WE, Armstrong DK, Moore KN, DiSilvestro PA, O'Malley DM, Tenney ME, Rose PG, Fracasso PM.

Gynecol Oncol. 2016 Feb;140(2):204-9. doi: 10.1016/j.ygyno.2015.11.024. Epub 2015 Nov 23.

14.

Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.

Goodfellow PJ, Billingsley CC, Lankes HA, Ali S, Cohn DE, Broaddus RJ, Ramirez N, Pritchard CC, Hampel H, Chassen AS, Simmons LV, Schmidt AP, Gao F, Brinton LA, Backes F, Landrum LM, Geller MA, DiSilvestro PA, Pearl ML, Lele SB, Powell MA, Zaino RJ, Mutch D.

J Clin Oncol. 2015 Dec 20;33(36):4301-8. doi: 10.1200/JCO.2015.63.9518. Epub 2015 Nov 9.

15.

Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice.

Cohn DE, Havrilesky LJ, Osann K, Lipscomb J, Hsieh S, Walker JL, Wright AA, Alvarez RD, Karlan BY, Bristow RE, DiSilvestro PA, Wakabayashi MT, Morgan R, Mukamel DB, Wenzel L.

Gynecol Oncol. 2015 Sep;138(3):712-6. doi: 10.1016/j.ygyno.2015.07.014. Epub 2015 Jul 12.

16.

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.

Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS; Breast Cancer Family Registry, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Gerdes AM, Ejlertsen B, Nielsen FC, Hansen TV, Osorio A, Benitez J, Conejero RA, Segota E, Weitzel JN, Thelander M, Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B, Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini L, Yannoukakos D, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brady A, Brewer C, Foo C, Evans DG, Frost D, Eccles D; EMBRACE, Douglas F, Cook J, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Tischkowitz M, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Cole T, Godwin AK, Isaacs C, Claes K, De Leeneer K, Meindl A, Gehrig A, Wappenschmidt B, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Schmutzler RK, Preisler-Adams S, Markov NB, Wang-Gohrke S, de Pauw A, Lefol C, Lasset C, Leroux D, Rouleau E, Damiola F; GEMO Study Collaborators, Dreyfus H, Barjhoux L, Golmard L, Uhrhammer N, Bonadona V, Sornin V, Bignon YJ, Carter J, Van Le L, Piedmonte M, DiSilvestro PA, de la Hoya M, Caldes T, Nevanlinna H, Aittomäki K, Jager A, van den Ouweland AM, Kets CM, Aalfs CM, van Leeuwen FE, Hogervorst FB, Meijers-Heijboer HE; HEBON, Oosterwijk JC, van Roozendaal KE, Rookus MA, Devilee P, van der Luijt RB, Olah E, Diez O, Teulé A, Lazaro C, Blanco I, Del Valle J, Jakubowska A, Sukiennicki G, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Agnarsson BA, Maugard C, Amadori A, Montagna M, Teixeira MR, Spurdle AB, Foulkes W, Olswold C, Lindor NM, Pankratz VS, Szabo CI, Lincoln A, Jacobs L, Corines M, Robson M, Vijai J, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Greene MH, Mai PL, Rennert G, Imyanitov EN, Mulligan AM, Glendon G, Andrulis IL, Tchatchou S, Toland AE, Pedersen IS, Thomassen M, Kruse TA, Jensen UB, Caligo MA, Friedman E, Zidan J, Laitman Y, Lindblom A, Melin B, Arver B, Loman N, Rosenquist R, Olopade OI, Nussbaum RL, Ramus SJ, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Mitchell G, Karlan BY, Lester J, Orsulic S, Stoppa-Lyonnet D, Thomas G, Simard J, Couch FJ, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC, Mazoyer S, Phelan CM, Sinilnikova OM, Cox DG.

Breast Cancer Res. 2015 Apr 25;17:61. doi: 10.1186/s13058-015-0567-2.

18.

Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy alone.

Robison K, Roque D, McCourt C, Stuckey A, DiSilvestro PA, Sung CJ, Steinhoff M, Granai CO, Moore RG.

Gynecol Oncol. 2014 Jun;133(3):416-20. doi: 10.1016/j.ygyno.2014.03.010. Epub 2014 Mar 11.

PMID:
24631445
19.

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.

Campos SM, Brady WE, Moxley KM, O'Cearbhaill RE, Lee PS, DiSilvestro PA, Rotmensch J, Rose PG, Thaker PH, O'Malley DM, Hanjani P, Zuna RE, Hensley ML.

Gynecol Oncol. 2014 Jun;133(3):537-41. doi: 10.1016/j.ygyno.2014.02.036. Epub 2014 Mar 1. Erratum in: Gynecol Oncol. 2014 Dec;135(3):624.

20.

Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.

DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH, Steinhoff MM, Monk BJ.

J Clin Oncol. 2014 Feb 10;32(5):458-64. doi: 10.1200/JCO.2013.51.4265. Epub 2014 Jan 6.

21.

A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, Yamada SD, Armstrong DK, Fracasso PM, Walker JL.

Gynecol Oncol. 2012 Dec;127(3):506-10. doi: 10.1016/j.ygyno.2012.08.037. Epub 2012 Aug 31.

22.

A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Dizon DS, Blessing JA, Penson RT, Drake RD, Walker JL, Johnston CM, Disilvestro PA, Fader AN.

Gynecol Oncol. 2012 May;125(2):367-71. doi: 10.1016/j.ygyno.2012.02.019. Epub 2012 Feb 21.

23.

Addressing clinical trials: can the multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program.

Kuroki L, Stuckey A, Hirway P, Raker CA, Bandera CA, DiSilvestro PA, Granai CO, Legare RD, Sakr BJ, Dizon DS.

Gynecol Oncol. 2010 Mar;116(3):295-300. doi: 10.1016/j.ygyno.2009.12.005. Epub 2009 Dec 29.

24.

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.

Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM.

J Clin Oncol. 2010 Jan 1;28(1):154-9. doi: 10.1200/JCO.2009.22.7900. Epub 2009 Nov 16.

PMID:
19917843
25.

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, Fiorica JV.

Gynecol Oncol. 2010 Jan;116(1):15-20. doi: 10.1016/j.ygyno.2009.09.025. Epub 2009 Oct 18.

26.

Urinary symptoms and impact on quality of life in women after treatment for endometrial cancer.

Erekson EA, Sung VW, DiSilvestro PA, Myers DL.

Int Urogynecol J Pelvic Floor Dysfunct. 2009 Feb;20(2):159-63. doi: 10.1007/s00192-008-0755-z. Epub 2008 Nov 5.

27.

Lower uterine segment involvement as a predictor for lymph node spread in endometrial carcinoma.

Madom LM, Brown AK, Lui F, Moore RG, Granai CO, Disilvestro PA.

Gynecol Oncol. 2007 Oct;107(1):75-8. Epub 2007 Jul 16.

PMID:
17629550
28.

Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer.

Gordinier ME, Dizon DS, Weitzen S, Disilvestro PA, Moore RG, Granai CO.

J Palliat Med. 2007 Feb;10(1):61-6.

PMID:
17298255
29.

Treatment of cervical intraepithelial neoplasia levels 2 and 3 with adapalene, a retinoid-related molecule.

DiSilvestro PA, DiSilvestro JM, Lernhardt W, Pfahl M, Mannel RS.

J Low Genit Tract Dis. 2001 Jan;5(1):33-7.

PMID:
17043560
30.

Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group.

DiSilvestro PA, Walker JL, Morrison A, Rose PG, Homesley H, Warshal D; Gynecologic Oncology Group.

Gynecol Oncol. 2006 Dec;103(3):1038-42. Epub 2006 Aug 4.

PMID:
16889823
31.
32.

Panniculectomy in morbidly obese gynecologic oncology patients.

Pearl ML, Valea FA, Disilvestro PA, Chalas E.

Int J Surg Investig. 2000;2(1):59-64.

PMID:
12774339
33.

Outcomes of endometrial cancer patients undergoing surgery with gynecologic oncology involvement.

Pearl ML, Villella JA, Valea FA, DiSilvestro PA, Chalas E.

Obstet Gynecol. 2002 Oct;100(4):724-9.

PMID:
12383541
34.

Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer.

Villella JA, Chaudhry T, Pearl ML, Valea F, DiSilvestro PA, Pollack S, Chalas E.

Gynecol Oncol. 2002 Sep;86(3):316-22.

PMID:
12217754
35.

A randomized controlled trial of a regular diet as the first meal in gynecologic oncology patients undergoing intraabdominal surgery.

Pearl ML, Frandina M, Mahler L, Valea FA, DiSilvestro PA, Chalas E.

Obstet Gynecol. 2002 Aug;100(2):230-4.

PMID:
12151142
36.

Ki-67 Expression in a Cervical Cancer Organotypic Model Correlates with Growth and EGF-R Expression.

DiSilvestro PA, Lightfoot SA, Benbrook DM.

J Low Genit Tract Dis. 1999 Apr;3(2):111-5.

PMID:
25950557
37.

Malignant mixed mesodermal tumors of the ovary.

DiSilvestro PA, Gajewski WH, Ludwig ME, Kourea H, Sung J, Granai CO.

Obstet Gynecol. 1995 Nov;86(5):780-2.

PMID:
7566848
38.

Ovarian cancer? What is the next step?

Granai CO, Gajewski WH, DiSilvestro PA, Falkenberry SS.

R I Med. 1995 May;78(5):146-8. Review. No abstract available.

PMID:
7606063
39.

'You may think I'm too old, but can't you treat my cancer?'.

DiSilvestro PA, Granai CO, Gajewski WH, Falkenberry SS.

R I Med. 1995 May;78(5):143-4. No abstract available.

PMID:
7606062

Supplemental Content

Loading ...
Support Center